We can’t show the full text here under this license.
Gene replacement therapy using AAV works in retinal models of AIPL1-related early vision loss
Updated
Abstract
Biallelic variations in the AIPL1 gene cause Leber congenital amaurosis subtype 4 (LCA4), an early-onset retinal dystrophy with severe sight impairment.
- Gene replacement therapy using adeno-associated virus may effectively rescue molecular features associated with LCA4 in human retinal organoid models.
- Treatment led to the restoration of retinal phosphodiesterase 6 levels and a reduction in elevated cyclic guanosine monophosphate (cGMP) levels.
- Transcriptomic analysis indicated changes in gene expression linked to the treatment and viral infection.
- Current evidence suggests that AIPL1 gene therapy could be a promising intervention for LCA4.
Simplified